AIKI Stock Overview
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics.
AIkido Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.30|
|52 Week High||US$16.58|
|52 Week Low||US$4.30|
|1 Month Change||0.31%|
|3 Month Change||13.16%|
|1 Year Change||-52.50%|
|3 Year Change||-82.68%|
|5 Year Change||-94.45%|
|Change since IPO||-100.00%|
Recent News & Updates
Alkido Pharma shareholders proposes to acquire company at $8/share in cash
Alkido Pharma's (NASDAQ:AIKI) significant stockholder Shalom Auerbach, who owns ~3.8% of its stock, announced that he has sent a letter proposing to acquire the company for $8/share in cash. This proposal to buy AIKI represents a 31% premium to the company’s most recent closing share price on Aug.8, 2022. It will provide substantial and immediate cash value for stockholders. The shareholder indicates that he will not hold this proposal open indefinitely and it is critical that the company meets with him by no later than Aug.23, 2022.
|AIKI||US Biotechs||US Market|
Return vs Industry: AIKI underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: AIKI underperformed the US Market which returned -10.2% over the past year.
|AIKI Average Weekly Movement||7.1%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: AIKI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AIKI's weekly volatility (7%) has been stable over the past year.
About the Company
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
AIkido Pharma Fundamentals Summary
|AIKI fundamental statistics|
Is AIKI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AIKI income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.91|
|Net Profit Margin||0.00%|
How did AIKI perform over the long term?See historical performance and comparison
Is AIKI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AIKI?
Other financial metrics that can be useful for relative valuation.
|What is AIKI's n/a Ratio?|
Price to Book Ratio vs Peers
How does AIKI's PB Ratio compare to its peers?
|AIKI PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
AGTC Applied Genetic Technologies
ENZN Enzon Pharmaceuticals
CRBP Corbus Pharmaceuticals Holdings
IDRA Idera Pharmaceuticals
AIKI AIkido Pharma
Price-To-Book vs Peers: AIKI is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (2.9x).
Price to Earnings Ratio vs Industry
How does AIKI's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: AIKI is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (1.9x)
Price to Book Ratio vs Fair Ratio
What is AIKI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.4x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate AIKI's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AIKI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AIKI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AIKI's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is AIkido Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AIKI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AIKI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AIKI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if AIKI's revenue is forecast to grow faster than the US market.
High Growth Revenue: AIKI is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AIKI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has AIkido Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AIKI is currently unprofitable.
Growing Profit Margin: AIKI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AIKI is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.
Accelerating Growth: Unable to compare AIKI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AIKI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: AIKI has a negative Return on Equity (-11.97%), as it is currently unprofitable.
Discover strong past performing companies
How is AIkido Pharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AIKI's short term assets ($61.6M) exceed its short term liabilities ($829.0K).
Long Term Liabilities: AIKI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AIKI is debt free.
Reducing Debt: AIKI has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AIKI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AIKI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 32.1% each year
Discover healthy companies
What is AIkido Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AIKI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AIKI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AIKI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AIKI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AIKI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Anthony Hayes (54 yo)
Mr. Anthony C. Hayes, Esq. has been the Chief Executive Officer and Principal Accounting Officer of Alkido Pharma Inc. (fka AIkido Pharma Inc. (formerly known as Spherix Incorporated)) since September 10,...
CEO Compensation Analysis
Compensation vs Market: Anthony's total compensation ($USD460.00K) is below average for companies of similar size in the US market ($USD759.98K).
Compensation vs Earnings: Anthony's compensation has been consistent with company performance over the past year.
Experienced Board: AIKI's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AIkido Pharma Inc.'s employee growth, exchange listings and data sources
- Name: AIkido Pharma Inc.
- Ticker: AIKI
- Exchange: NasdaqCM
- Founded: 1967
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$30.774m
- Shares outstanding: 5.00m
- Website: https://www.aikidopharma.com
Number of Employees
- AIkido Pharma Inc.
- One Rockefeller Plaza
- 11th Floor
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.